Back to top
more

KALA BIO, Inc. (KALA)

(Delayed Data from NSDQ)

$6.64 USD

6.64
876

+0.13 (1.97%)

Updated May 23, 2024 10:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Has Kala Pharmaceuticals (KALA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (KALA) Outperforming Other Medical Stocks This Year?

5 Stocks Up on Signs of Slowdown in Coronavirus Cases

by Zacks Equity Research

Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.

Nitish Marwah headshot

3 Breakout Stocks for Explosive Returns

by Nitish Marwah

Picking breakout stocks is one of the most favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.

Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

by Zacks Equity Research

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Is Kala Pharmaceuticals (KALA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (KALA) Outperforming Other Medical Stocks This Year?

Kala Pharmaceuticals, Inc. (KALA) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Kala Pharmaceuticals, Inc. (KALA).

Top Ranked Momentum Stocks to Buy for March 10th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 10th

Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Acorda (ACOR) beat earnings and revenue estimates in the fourth quarter of 2019.

Agios' (AGIO) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Agios (AGIO) rides high on earnings and revenue beat in the fourth quarter of 2019.

Blueprint Medicines (BPMC) Q4 Loss Narrows, Revenues Top Mark

by Zacks Equity Research

Blueprint Medicines (BPMC) impresses investors with fourth-quarter earnings and revenue beat.

Inovio Gets FDA Nod to Begin Study on INO-3107, Stock Gains

by Zacks Equity Research

The FDA accepts Inovio's (INO) IND application for INO-3107 to initiate a phase I/II study for the treatment of recurrent respiratory papillomatosis, a rare disease caused by HPV. Stock up.

Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan

by Zacks Equity Research

The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.

Aimmune's Palforzia Wins FDA Approval for Peanut Allergy

by Zacks Equity Research

Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.

Intercept (ICPT) Concludes Enrollment in Study on NASH Drug

by Zacks Equity Research

Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.

Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon

by Zacks Equity Research

A low-key week for the biotech sector with a few pipeline and regulatory updates.

Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Kala Pharma (KALA) delivered earnings and revenue surprises of -1.49% and -59.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

Kala Pharmaceuticals (KALA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Kala Pharma (KALA) delivered earnings and revenue surprises of 5.41% and -21.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Kala Pharma (KALA) delivered earnings and revenue surprises of 17.28% and 43.78%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Kala Pharmaceuticals (KALA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Kala Pharmaceuticals (KALA) stock based on the movements in the options market lately.

Implied Volatility Surging for Kala Pharmaceuticals (KALA) Stock Options

by Zacks Equity Research

Kala Pharmaceuticals (KALA) needs investors to pay close attention to the stock based on moves in the options market lately.

Will Cigna (CI) Q3 Earnings Gain on Revenue Growth?

by Zacks Equity Research

Cigna (CI) Q3 earnings should gain from revenue and membership growth

Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

by Zacks Equity Research

Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.